NICE recommends Norgine’s Pedmarqsi

UK health technology assessor the National Institute for Health and Care Excellence (NICE) today recommending Pedmarqsi (anhydrous sodium thiosulfate), from British specialty pharma firm Norgine Pharmaceuticals, for the prevention of cisplatin-induced ototoxicity (CIO) in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors.

Norgine pointed out that Pedmarqsi is the first and only treatment specifically tailored for use in paediatric patients with localized solid tumors for the prevention of ototoxicity. This decision from the NICE represents an important milestone for the young patients who will benefit from this medicine.

Commenting on the development, Mark Ashton, Norgine’s UK general manager, said: “We are delighted that the National Institute for Health and Care Excellence (NICE) has recommended Pedmarqsi, highlighting the value it brings to this important unmet medical need. It also recognizes the positive impact that this treatment could have not only on the quality of life, but importantly, on the future of these children. At Norgine, we are excited to build our presence in pediatric oncology, as we aim to bring transformative and life-changing medicines to children in the UK.”